7S5Q
Crystal structure of SARS-CoV-2 B.1.351 variant receptor binding domain in complex with neutralizing antibodies CS44 and COVA1-16
7S5Q の概要
エントリーDOI | 10.2210/pdb7s5q/pdb |
分子名称 | Spike protein S1, CS44 Heavy chain, CS44 Light chain, ... (9 entities in total) |
機能のキーワード | sars-cov-2, coronavirus, antibody, fab, voc, beta, b.1.351, spike, rbd, immune system, viral protein-immune system complex, viral protein/immune system |
由来する生物種 | Severe acute respiratory syndrome coronavirus 2 (2019-nCoV, SARS-CoV-2) 詳細 |
タンパク質・核酸の鎖数 | 5 |
化学式量合計 | 123688.44 |
構造登録者 | |
主引用文献 | Reincke, S.M.,Yuan, M.,Kornau, H.C.,Corman, V.M.,van Hoof, S.,Sanchez-Sendin, E.,Ramberger, M.,Yu, W.,Hua, Y.,Tien, H.,Schmidt, M.L.,Schwarz, T.,Jeworowski, L.M.,Brandl, S.E.,Rasmussen, H.F.,Homeyer, M.A.,Stoffler, L.,Barner, M.,Kunkel, D.,Huo, S.,Horler, J.,von Wardenburg, N.,Kroidl, I.,Eser, T.M.,Wieser, A.,Geldmacher, C.,Hoelscher, M.,Ganzer, H.,Weiss, G.,Schmitz, D.,Drosten, C.,Pruss, H.,Wilson, I.A.,Kreye, J. SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies. Science, 375:782-787, 2022 Cited by PubMed Abstract: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Beta variant of concern (VOC) resists neutralization by major classes of antibodies from COVID-19 patients and vaccinated individuals. In this study, serum of Beta-infected patients revealed reduced cross-neutralization of wild-type virus. From these patients, we isolated Beta-specific and cross-reactive receptor-binding domain (RBD) antibodies. The Beta-specificity results from recruitment of VOC-specific clonotypes and accommodation of mutations present in Beta and Omicron into a major antibody class that is normally sensitive to these mutations. The Beta-elicited cross-reactive antibodies share genetic and structural features with wild type-elicited antibodies, including a public VH1-58 clonotype that targets the RBD ridge. These findings advance our understanding of the antibody response to SARS-CoV-2 shaped by antigenic drift, with implications for design of next-generation vaccines and therapeutics. PubMed: 35076281DOI: 10.1126/science.abm5835 主引用文献が同じPDBエントリー |
実験手法 | X-RAY DIFFRACTION (2.88 Å) |
構造検証レポート
検証レポート(詳細版)をダウンロード